TY  - GEN
N2  - In the absence of a prophylactic vaccine and curative strategies, the daily use of antiretroviral therapy (ART) is essential for preventing and maintaining HIV infection. Although ART plays a vital role in decreasing the numbers of new infections and AIDS-related deaths, transforming this once deadly disease into a manageable condition, we are also observing an increase in global antiretroviral (ARV) drug resistance. Because ART requires daily oral use for a lifetime, suboptimal treatment adherence will accelerate the development of drug resistance. To combat this problem, multiple classes of ARV drugs with different mechanisms of action are being incorporated into first-line drug regimens; however, drug resistance against newer forms of ARV drugs will ultimately rise with increasing usage. To this end, investigating different drug targets with higher genetic barriers to resistance and drug formulations to allow for less frequent dosing will aid in the slowing of the HIV epidemic. This dissertation hypothesizes that an anti-CCR5 antibody Leronlimab (PRO 140; PA14) can phenocopy the natural resistance observed in homozygous CCR5D32 individuals to prevent viral acquisition and suppress viremia.
DO  - 10.6083/z603qz138
DO  - DOI
AB  - In the absence of a prophylactic vaccine and curative strategies, the daily use of antiretroviral therapy (ART) is essential for preventing and maintaining HIV infection. Although ART plays a vital role in decreasing the numbers of new infections and AIDS-related deaths, transforming this once deadly disease into a manageable condition, we are also observing an increase in global antiretroviral (ARV) drug resistance. Because ART requires daily oral use for a lifetime, suboptimal treatment adherence will accelerate the development of drug resistance. To combat this problem, multiple classes of ARV drugs with different mechanisms of action are being incorporated into first-line drug regimens; however, drug resistance against newer forms of ARV drugs will ultimately rise with increasing usage. To this end, investigating different drug targets with higher genetic barriers to resistance and drug formulations to allow for less frequent dosing will aid in the slowing of the HIV epidemic. This dissertation hypothesizes that an anti-CCR5 antibody Leronlimab (PRO 140; PA14) can phenocopy the natural resistance observed in homozygous CCR5D32 individuals to prevent viral acquisition and suppress viremia.
T1  - Anti-CCR5 antibody for HIV prevention, treatment, and cure
DA  - 2022
AU  - Chang, Xiao L.
L1  - https://digitalcollections.ohsu.edu/record/9480/files/Chang.Xiaolan.2022.pdf
PB  - Oregon Health and Science University
PY  - 2022
ID  - 9480
L4  - https://digitalcollections.ohsu.edu/record/9480/files/Chang.Xiaolan.2022.pdf
KW  - Macaca mulatta
KW  - HIV
KW  - CD4-Positive T-Lymphocytes
KW  - Acquired Immunodeficiency Syndrome
KW  - ccr5
KW  - antibody
KW  - receptor occupancy
KW  - nonhuman primates
TI  - Anti-CCR5 antibody for HIV prevention, treatment, and cure
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9480/files/Chang.Xiaolan.2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9480/files/Chang.Xiaolan.2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9480/files/Chang.Xiaolan.2022.pdf
ER  -